NAGLAZYME
(Naglazyme)PreclinicalSmall molecule
BioMarin PharmaceuticalNAGLAZYME is one of 12 small molecule programs targeting LAM. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
11
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
12 competitors in LAM
#DrugCompanyPhaseTrials
1Kesimpta
NovartisApproved
Rituxan
RochePhase 2
Budesonide/formoterol
AstraZenecaPhase 3
Humira
Boehringer IngelheimPhase 2
Cosentyx
Johnson & JohnsonPhase 2
Kineret
AmgenPhase 2
Roactemra
KKarolinska Institutet
Phase 2
Stelara
BBiocon Biologics UK PLC
Phase 2
Colesevelam Hcl
Daiichi SankyoPreclinical
NAGLAZYME
BioMarin PharmaceuticalPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
May 31, 2005
NAGLAZYME
BLA BLA125117
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Naglazyme. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company